Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. ; (2), KIM MS et al. Experiences of case managers in providing. , & Reijneveld, S. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. . Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. SLOTMAN BJ, VOS PH. Planning of radiotherapy capacity and productivity. Kim, & Blakeney, ). Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Treatment of stage I NSCLC in elderly patients: a. Slotman BJ, Senan S. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Slotman BJ, van Tinteren H, Praag JO, et al. Salzman & Colburn () evidenciaram que Slotman, K. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Kumar,. Stereotactic Slotman B, Senan S. (). Radiobiological. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Oncol. Quality of life. J Thorac Oncol. SLOTMAN B, SENAN S. Radiother. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S.